Related references
Note: Only part of the references are listed.Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment
William J. Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results
Geert R. D'Haens et al.
GASTROENTEROLOGY (2022)
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis
Juan S. Lasa et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results
Julian Panes et al.
GASTROENTEROLOGY (2022)
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
Silvio Danese et al.
LANCET (2022)
CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease
Christopher Ma et al.
GASTROENTEROLOGY (2022)
Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis
Juan S. Lasa et al.
DRUG SAFETY (2021)
Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease
Stefan Schreiber et al.
GASTROENTEROLOGY (2021)
Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis
Siddharth Singh et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
Brian G. Feagan et al.
LANCET (2021)
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2TOUCHSTONE Study
William J. Sandborn et al.
JOURNAL OF CROHNS & COLITIS (2021)
Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
Siddharth Singh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2020)
Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis
Pablo Olivera et al.
GASTROENTEROLOGY (2020)
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2020)
Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses
Kenji Watanabe et al.
JOURNAL OF GASTROENTEROLOGY (2020)
Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease
Daniele Piovani et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Long-term safety of vedolizumab for inflammatory bowel disease
Edward V. Loftus et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Pathophysiology of Inflammatory Bowel Diseases
John T. Chang
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy
Remo Panaccione et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial
Baili Chen et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2020)
Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study
Satoshi Motoya et al.
PLOS ONE (2019)
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
B. E. Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
Bruce E. Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Safety of biological therapies in ulcerative colitis: An umbrella review of meta-analyses
Stefanos Bonovas et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2018)
Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study
Nabeel Khan et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials
Remo Panaccione et al.
JOURNAL OF CROHNS & COLITIS (2018)
The risk for opportunistic infections in inflammatory bowel disease with biologics: an update
Zachary A. Borman et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2018)
Next generation of small molecules in inflammatory bowel disease
Pablo Olivera et al.
GUT (2017)
JAK inhibition in inflammatory bowel disease
Pablo Olivera et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)
Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis
Eric D. Shah et al.
INFLAMMATORY BOWEL DISEASES (2017)
Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study)
Toshifumi Hibi et al.
JOURNAL OF GASTROENTEROLOGY (2017)
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease
Francis A. Farraye et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2017)
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
Peter G. Pappas et al.
CLINICAL INFECTIOUS DISEASES (2016)
First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis
Taku Kobayashi et al.
JOURNAL OF GASTROENTEROLOGY (2016)
Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis
Stefanos Bonovas et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial
Takayuki Matsumoto et al.
JOURNAL OF CROHNS & COLITIS (2016)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease
P. Luthra et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance
K. L. Winthrop et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients With Moderate to Severe Active Ulcerative Colitis
Xue-Liang Jiang et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2015)
Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3
Jean-Frederic Colombel et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Effects of Vedolizumab Induction Therapy for Patients With Crohn's Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
Bruce E. Sands et al.
GASTROENTEROLOGY (2014)
Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2014)
Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2014)
Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease
Mamoru Watanabe et al.
JOURNAL OF CROHNS & COLITIS (2014)
Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
J. F. Rahier et al.
JOURNAL OF CROHNS & COLITIS (2014)
Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
Yasuo Suzuki et al.
JOURNAL OF GASTROENTEROLOGY (2014)
Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease
M. D. Long et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial
Paul Rutgeerts et al.
GASTROENTEROLOGY (2012)
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Long-term infliximab maintenance therapy for ulcerative colitis: The ACT-1 and-2 extension studies
Walter Reinisch et al.
INFLAMMATORY BOWEL DISEASES (2012)
Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE
Robert Lofberg et al.
INFLAMMATORY BOWEL DISEASES (2012)
Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study
Asit Parikh et al.
INFLAMMATORY BOWEL DISEASES (2012)
Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease
Mamoru Watanabe et al.
JOURNAL OF CROHNS & COLITIS (2012)
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial
Remo Panaccione et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY (2011)
Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
Walter Reinisch et al.
GUT (2011)
The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy
S. Lichtiger et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months
Gary R. Lichtenstein et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
Brian G. Feagan et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
William J. Sandborn et al.
GASTROENTEROLOGY (2008)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Maintenance therapy with certolizumab pegol for Crohn's disease
Stefan Schreiber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Adalimumab induction therapy for Crohn disease previously treated with infliximab - A randomized trial
William J. Sandborn et al.
ANNALS OF INTERNAL MEDICINE (2007)
Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE trial
Stephan R. Targan et al.
GASTROENTEROLOGY (2007)
Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab
Bruce E. Sands et al.
INFLAMMATORY BOWEL DISEASES (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Infliximab plus azathioprine for steroid-dependent Crohn's disease patients:: A randomized placebo-controlled trial
M Lémann et al.
GASTROENTEROLOGY (2006)
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy
TA Yousry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease
S Schreiber et al.
GASTROENTEROLOGY (2005)
Brief report - Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
G Van Assche et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study
TA Winter et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Infliximab in moderately severe glucocorticoid resistant ulcerative colitis:: a randomised controlled trial
CSJ Probert et al.
GUT (2003)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease
FH Gordon et al.
GASTROENTEROLOGY (2001)
Share Paper
